Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?

H. Meltzer

DOI: https://doi.org/10.1007/s002130000465

2000-06-01

Psychopharmacology

Abstract:

What problem does this paper attempt to address?

Diagnostics of Ebola virus

Aurora Bettini,Daniele Lapa,Anna Rosa Garbuglia

DOI: https://doi.org/10.3389/fpubh.2023.1123024

IF: 5.2

2023-02-24

Frontiers in Public Health

Abstract:Ebola is a highly pathogenic virus, which in humans reaches a mortality rate above 50%. Due to a lack of laboratories in territories where Ebola viruses are endemic and the limited number of surveillance programmes, tests for the confirmation of suspected cases of Ebola are often performed in Reference Laboratories. While this provides guarantees regarding the accuracy of results, the shipment of samples to a centralized facility where the diagnostic test can be performed and the time required to achieve the results takes several days, which increases costs and entails delays in the isolation of positive subjects and therapeutic intervention with negative consequences both for patients and the community. Molecular tests have been the most frequently used tool in Ebola diagnosis in recent outbreaks. One of the most commonly used molecular tests is the Real-Star Altona, which targets a conserved area of the L gene. This assay showed different sensitivities depending on the Ebola virus: 471 copies/mL (EBOV) and 2871 copies/ml (SUDAN virus). The Cepheid system also showed good sensitivity (232 copies/mL). The LAMP platform is very promising because, being an isothermal reaction, it does not require high-precision instrumentation and can be considered a Point of Care (PoC) tool. Its analytical sensitivity is 1 copy/reaction. However, since data from real life studies are not yet available, it is premature to give any indications on its feasibility. Moreover, in November 2014, the WHO recommended the development of rapid diagnostic tests (RDT) according to ASSURED criteria. Several RDT assays have since been produced, most of which are rapid tests based on the search for antibody anti-Ebola viral proteins with immunochromatographic methods. Several viral antigens are used for this purpose: VP40, NP and GP. These assays show different sensitivities according to the protein used: VP40 57.4–93.1%, GP 53–88.9% and 85% for NP compared to reference molecular assays. From these results, it can be deduced that no RDT reaches the 99% sensitivity recommended by the WHO and therefore any RDT negative results in suspected cases should be confirmed with a molecular test.

public, environmental & occupational health
Development and Evaluation of a Rapid and Sensitive EBOV-RPA Test for Rapid Diagnosis of Ebola Virus Disease

Mingjuan Yang,Yuehua Ke,Xuesong Wang,Hang Ren,Wei Liu,Huijun Lu,Wenyi Zhang,Shiwei Liu,Guohui Chang,Shuguang Tian,Lihua Wang,Liuyu Huang,Chao Liu,Ruifu Yang,Zeliang Chen

DOI: https://doi.org/10.1038/srep26943

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Confirming Ebola virus disease (EVD), a deadly infectious disease, requires real-time RT-PCR, which takes up to a few hours to yield results. Therefore, a rapid diagnostic assay is imperative for EVD diagnosis. A rapid nucleic acid test based on recombinase polymerase amplification (EBOV-RPA) was developed to specifically detect the 2014 outbreak strains. The EBOV-RPA assay was evaluated by testing samples from suspected EVD patients in parallel with RT-PCR. An EBOV-RPA, which could be completed in 20 min, was successfully developed. Of 271 patients who tested positive for Ebola virus by RT-PCR, 264 (sensitivity: 97%, 95% CI: 95.5–99.3%) were positive by EBOV-RPA; 101 of 104 patients (specificity: 97%, 95% CI: 93.9–100%) who tested negative by RT-PCR were also negative by EBOV-RPA. The sensitivity values for samples with a Ct value of <34, which accounted for 95.59% of the samples, was 100%. Discordant samples positive by RT-PCR but negative by EBOV-RPA had significantly high Ct values. Results of external quality assessment samples with EBOV-RPA were 100%, consistent with those of RT-PCR. The EBOV-RPA assay showed 97% sensitivity and 97% specificity for all EVD samples tested, making it a rapid and sensitive test for EVD diagnosis.
Ebolavirus diagnosis made simple, comparable and faster than molecular detection methods: preparing for the future

Ameh S James,Shawn Todd,Nina M Pollak,Glenn A Marsh,Joanne Macdonald

DOI: https://doi.org/10.1186/s12985-018-0985-8

2018-04-23

Abstract:Background: The 2014/2015 Ebolavirus outbreak resulted in more than 28,000 cases and 11,323 reported deaths, as of March 2016. Domestic transmission of the Guinea strain associated with the outbreak occurred mainly in six African countries, and international transmission was reported in four countries. Outbreak management was limited by the inability to rapidly diagnose infected cases. A further fifteen countries in Africa are predicted to be at risk of Ebolavirus outbreaks in the future as a consequence of climate change and urbanization. Early detection of cases and reduction of transmission rates is critical to prevent and manage future severe outbreaks. We designed a rapid assay for detection of Ebolavirus using recombinase polymerase amplification, a rapid isothermal amplification technology that can be combined with portable lateral flow detection technology. The developed rapid assay operates in 30 min and was comparable with real-time TaqMan™ PCR. Methods: Designed, screened, selected and optimized oligonucleotides using the NP coding region from Ebola Zaire virus (Guinea strain). We determined the analytical sensitivity of our Ebola rapid molecular test by testing selected primers and probe with tenfold serial dilutions (1.34 × 1010- 1.34 × 101 copies/μL) of cloned NP gene from Mayinga strain of Zaire ebolavirus in pCAGGS vector, and serially diluted cultured Ebolavirus as established by real-time TaqMan™ PCR that was performed using ABI7500 in Fast Mode. We tested extracted and reverse transcribed RNA from cultured Zaire ebolavirus strains - Mayinga, Gueckedou C05, Gueckedou C07, Makona, Kissidougou and Kiwit. We determined the analytical specificity of our assay with related viruses: Marburg, Ebola Reston and Ebola Sudan. We further tested for Dengue virus 1-4, Plasmodium falciparum and West Nile Virus (Kunjin strain). Results: The assay had a detection limit of 134 copies per μL of plasmid containing the NP gene of Ebolavirus Mayinga, and cultured Ebolavirus and was highly specific for the Zaire ebolavirus species, including the Guinea strain responsible for the 2014/2015 outbreak. The assay did not detect related viruses like Marburg, Reston, or Sudan viruses, and other pathogens likely to be isolated from clinical samples. Conclusions: Our assay could be suitable for implementation in district and primary health laboratories, as only a heating block and centrifuge is required for operation. The technique could provide a pathway for rapid screening of patients and animals for improved management of outbreaks.
Comparative Evaluation of the Diagnostic Performance of the Prototype Cepheid GeneXpert Ebola Assay

Petrus Jansen van Vuren,Antoinette Grobbelaar,Nadia Storm,Ousman Conteh,Kelfala Konneh,Abdul Kamara,Ian Sanne,Janusz T Paweska

DOI: https://doi.org/10.1128/JCM.02724-15

Abstract:The Ebola virus disease (EVD) outbreak in West Africa has highlighted an urgent need for point-of-care (POC) assays for the diagnosis of this devastating disease in resource-limited African countries. The diagnostic performance characteristics of a prototype Cepheid GeneXpert Ebola POC used to detect Ebola virus (EBOV) in stored serum and plasma samples collected from suspected EVD cases in Sierra Leone in 2014 and 2015 was evaluated. The GeneXpert Ebola POC is a self-contained single-cartridge automated system that targets the glycoprotein (GP) and nucleoprotein (NP) genes of EBOV and yields results within 90 min. Results from 281 patient samples were compared to the results of a TaqMan real-time reverse transcription-PCR (RT-PCR) targeting the polymerase gene and performed on two real-time PCR machines. Agreement between the three platforms was 100% at cycle threshold (CT) values of ≤34.99, but discordant results were noted between CT values of 35 and 45.The diagnostic sensitivity of the three platforms was 100% in 91 patient samples that were confirmed to be infectious by virus isolation. All three molecular platforms detected viral EBOV RNA in additional samples that did not contain viable EBOV. The analytical sensitivity of the GeneXpert Ebola POC for the detection of NP was higher, and comparable to that of polymerase gene detection, than that for the detection of GP when using a titrated laboratory stock of EBOV. There was no detectable cross-reactivity with other hemorrhagic fever viruses or arboviruses. The GeneXpert Ebola POC offers an easy to operate and sensitive diagnostic tool that can be used for the rapid screening of suspected EVD cases in treatment or in holding centers during EVD outbreaks.
Analytical Performance Characteristics of the Cepheid GeneXpert Ebola Assay for the Detection of Ebola Virus

Benjamin A Pinsky,Malaya K Sahoo,Johanna Sandlund,Marika Kleman,Medha Kulkarni,Per Grufman,Malin Nygren,Robert Kwiatkowski,Ellen Jo Baron,Fred Tenover,Blake Denison,Russell Higuchi,Reuel Van Atta,Neil Reginald Beer,Alda Celena Carrillo,Pejman Naraghi-Arani,Chad E Mire,Charlene Ranadheera,Allen Grolla,Nina Lagerqvist,David H Persing

DOI: https://doi.org/10.1371/journal.pone.0142216

IF: 3.7

2015-11-12

PLoS ONE

Abstract:Background: The recently developed Xpert® Ebola Assay is a novel nucleic acid amplification test for simplified detection of Ebola virus (EBOV) in whole blood and buccal swab samples. The assay targets sequences in two EBOV genes, lowering the risk for new variants to escape detection in the test. The objective of this report is to present analytical characteristics of the Xpert® Ebola Assay on whole blood samples. Methods and findings: This study evaluated the assay's analytical sensitivity, analytical specificity, inclusivity and exclusivity performance in whole blood specimens. EBOV RNA, inactivated EBOV, and infectious EBOV were used as targets. The dynamic range of the assay, the inactivation of virus, and specimen stability were also evaluated. The lower limit of detection (LoD) for the assay using inactivated virus was estimated to be 73 copies/mL (95% CI: 51-97 copies/mL). The LoD for infectious virus was estimated to be 1 plaque-forming unit/mL, and for RNA to be 232 copies/mL (95% CI 163-302 copies/mL). The assay correctly identified five different Ebola viruses, Yambuku-Mayinga, Makona-C07, Yambuku-Ecran, Gabon-Ilembe, and Kikwit-956210, and correctly excluded all non-EBOV isolates tested. The conditions used by Xpert® Ebola for inactivation of infectious virus reduced EBOV titer by ≥6 logs. Conclusion: In summary, we found the Xpert® Ebola Assay to have high analytical sensitivity and specificity for the detection of EBOV in whole blood. It offers ease of use, fast turnaround time, and remote monitoring. The test has an efficient viral inactivation protocol, fulfills inclusivity and exclusivity criteria, and has specimen stability characteristics consistent with the need for decentralized testing. The simplicity of the assay should enable testing in a wide variety of laboratory settings, including remote laboratories that are not capable of performing highly complex nucleic acid amplification tests, and during outbreaks where time to detection is critical.
Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus

Verena Krähling,Dirk Becker,Cornelius Rohde,Markus Eickmann,Yonca Eroğlu,Astrid Herwig,Romy Kerber,Katharina Kowalski,Júlia Vergara-Alert,Stephan Becker,European Mobile Laboratory consortium,Miles W Carroll,Roger Hewson,Joseph Akoi Bore,Raymond Koundouno,Saïd Abdellati,Babak Afrough,John Aiyepada,Patience Akhilomen,Danny Asogun,Barry Atkinson,Marlis Badusche,Amadou Bah,Simon Bate,Jan Baumann,Beate Becker-Ziaja,Anne Bocquin,Benny Borremans,Andrew Bosworth,Jan Peter Boettcher,Angela Cannas,Fabrizio Carletti,Concetta Castilletti,Simon Clark,Francesca Colavita,Sandra Diederich,Adomeh Donatus,Sophie Duraffour,Deborah Ehichioya,Heinz Ellerbrok,Maria Dolores Fenandez-Garcia,Alexandra Fizet,Erna Fleischmann,Sophie Gryseels,Antje Hermelink,Julia Hinzmann,Ute Hopf-Guevara,Yemisi Ighodalo,Lisa Jameson,Anne Kelterbaum,Zoltan Kis,Stefan Kloth,Claudia Kohl,Miša Korva,Annette Kraus,Eeva Kuisma,Andreas Kurth,Britta Liedigk,Christopher H Logue,Anja Lüdtke,Piet Maes,James McCowen,Stéphane Mély,Marc Mertens,Silvia Meschi,Benjamin Meyer,Janine Michel,Peter Molkenthin,César Muñoz-Fontela,Doreen Muth,Edmund N C Newman,Didier Ngabo,Lisa Oestereich,Jennifer Okosun,Thomas Olokor,Racheal Omiunu,Emmanuel Omomoh,Elisa Pallasch,Bernadett Pályi,Jasmine Portmann,Thomas Pottage,Catherine Pratt,Simone Priesnitz,Serena Quartu,Julie Rappe,Johanna Repits,Martin Richter,Martin Rudolf,Andreas Sachse,Kristina Maria Schmidt,Gordian Schudt,Thomas Strecker,Ruth Thom,Stephen Thomas,Ekaete Tobin,Howard Tolley,Jochen Trautner,Tine Vermoesen,Inês Vitoriano,Matthias Wagner,Svenja Wolff,Constanze Yue,Maria Rosaria Capobianchi,Tatjana Avšic-Županc,Andreas Nitsche,Marc Strasser,Giuseppe Ippolito,Kilian Stoecker,Martin Gabriel,Hervé Raoul,Antonino Di Caro,Roman Wölfel,Stephan Günther

DOI: https://doi.org/10.1007/s00430-015-0438-6

Abstract:The 2014 Zaire Ebola virus (ZEBOV) outbreak in West Africa represents an international public health concern. Highly sensitive and precise diagnostic tools are needed. In the present study, we developed a ZEBOV-specific enzyme-linked immunosorbent assay (ELISA) using inactivated ZEBOV isolate Makona from March 2014. Mock antigen was used to address nonspecific binding. Specificity, reproducibility and precision were determined to measure assay performance. The ZEBOV ELISA proved to be specific (96 %), reproducible and precise (Intra-assay CV 8 %, Inter-assay CV 18 %). Using the human monoclonal antibody KZ52, we showed that the ELISA was able to detect conformation-specific antibodies. Monitoring antibody development in 29 PCR-positive EBOV disease (EVD) patients revealed seroconversion in all cases. In addition, the ELISA was used to detect ZEBOV glycoprotein (GP)-specific antibodies in a vaccinated volunteer from day 14 until 5 years post-vaccination with a VSV-ZEBOV candidate vaccine. The results demonstrate the high reproducibility, specificity and sensitivity of this newly developed ELISA, which is suitable for the detection of specific antibody responses directed against different ZEBOV proteins in EVD patients and against the ZEBOV surface glycoprotein GP in vaccinated individuals.
Digital Rolling Circle Amplification-Based Detection of Ebola and Other Tropical Viruses

Sibel Ciftci,Felix Neumann,Samir Abdurahman,K Sofia Appelberg,Ali Mirazimi,Mats Nilsson,Narayanan Madaboosi

DOI: https://doi.org/10.1016/j.jmoldx.2019.10.014

Abstract:Emerging tropical viruses have caused serious outbreaks during the recent years, such as Ebola virus (EBOV) in 2014 and the most recent in 2018 to 2019 in Congo. Thus, immediate diagnostic attention is demanded at the point of care in resource-limited settings, because the performance and the operational parameters of conventional EBOV testing are limited. Especially, their sensitivity, specificity, and coverage of other tropical disease viruses make them unsuitable for diagnostic at the point of care. Here, a padlock probe (PLP)-based rolling circle amplification (RCA) method for the detection of EBOV is presented. For this, a set of PLPs, separately targeting the viral RNA and complementary RNA of all seven EBOV genes, was used in the RCA assay and validated on virus isolates from cell culture. The assay was then translated for testing clinical samples, and simultaneous detection of both EBOV RNA types was demonstrated. For increased sensitivity, the RCA products were enriched on a simple and pump-free microfluidic chip. Because PLPs and RCA are inherently multiplexable, we demonstrate the extension of the probe panel for the simultaneous detection of the tropical viruses Ebola, Zika, and Dengue. The demonstrated high specificity, sensitivity, and multiplexing capability in combination with the digital quantification rendered the assay a promising diagnostic tool toward tropical virus detection at the point of care.
Rapid detection of Ebolavirus using isothermal recombinase‐aided amplification

Arianna Ceruti,Martin Faye,Moussa M. Diagne,Rea M. Kobialka,Sheila Makiala‐Mandanda,Ousmane Faye,Oumar Faye,Ahmed A. El Wahed,Manfred Weidmann

DOI: https://doi.org/10.1002/jmv.29744

IF: 20.693

2024-06-16

Journal of Medical Virology

Abstract:Ebolavirus disease (EVD) is an often‐lethal disease caused by the genus Ebolavirus (EBOV). Although vaccines are being developed and recently used, outbreak control still relies on a combination of various factors, including rapid identification of EVD cases. This allows rapid patient isolation and control measure implementation. Ebolavirus diagnosis is performed in treatment centers or reference laboratories, which usually takes a few hours to days to confirm the outbreak or deliver a clear result. A fast and field‐deployable molecular detection method, such as the isothermal amplification recombinase‐aided amplification (RAA), could significantly reduce sample‐to‐result time. In this study, a RT‐RAA assay was evaluated for EBOV detection. Various primer and probe combinations were screened; analytical sensitivity and cross‐specificity were tested. A total of 40 archived samples from the 2014 to 2016 Ebola outbreak in West Africa were tested with both the reference method real‐time RT‐PCR and the established RT‐RAA assay. The assay could detect down to 22.6 molecular copies per microliter. No other pathogens were detected with the Ebolavirus RT‐RAA assay. Testing 40 samples yield clinical sensitivity and specificity of 100% each. This rapid isothermal RT‐RAA assay can replace the previous RT‐RPA and continue to offer rapid EBOV diagnostics.

virology
Ebola Virus Disease Diagnostics, Sierra Leone: Analysis of Real-time Reverse Transcription-Polymerase Chain Reaction Values for Clinical Blood and Oral Swab Specimens

Bobbie R Erickson,Tara K Sealy,Tim Flietstra,Laura Morgan,Brima Kargbo,Victor E Matt-Lebby,Aridth Gibbons,Ayan K Chakrabarti,James Graziano,Lance Presser,Mike Flint,Brian H Bird,Shelley Brown,John D Klena,Dianna M Blau,Aaron C Brault,Jessica A Belser,Johanna S Salzer,Amy J Schuh,Michael Lo,Marko Zivcec,Rachael A Priestley,Meredith Pyle,Christin Goodman,Scott Bearden,Brian R Amman,Alison Basile,Éric Bergeron,Michael D Bowen,Kimberly A Dodd,Molly M Freeman,Laura K McMullan,Christopher D Paddock,Brandy J Russell,Angela J Sanchez,Jonathan S Towner,David Wang,Galina E Zemtsova,Robyn A Stoddard,Maryann Turnsek,Lisa Wiggleton Guerrero,Shannon L Emery,Janae Stovall,Markus H Kainulainen,Jamie L Perniciaro,Slavica Mijatovic-Rustempasic,Gulchekhra Shakirova,Jörn Winter,Christopher Sexton,Feng Liu,Kimetha Slater,Raydel Anderson,Lauren Andersen,Cheng-Feng Chiang,Wen-Pin Tzeng,Samuel J Crowe,Matthew J Maenner,Christina F Spiropoulou,Stuart T Nichol,Ute Ströher

DOI: https://doi.org/10.1093/infdis/jiw296

2016-10-15

Abstract:During the Ebola virus outbreak of 2013-2016, the Viral Special Pathogens Branch field laboratory in Sierra Leone tested approximately 26 000 specimens between August 2014 and October 2015. Analysis of the B2M endogenous control Ct values showed its utility in monitoring specimen quality, comparing results with different specimen types, and interpretation of results. For live patients, blood is the most sensitive specimen type and oral swabs have little diagnostic utility. However, swabs are highly sensitive for diagnostic testing of corpses.
Establishing Ebola Virus Disease (EVD) diagnostics using GeneXpert technology at a mobile laboratory in Liberia: Impact on outbreak response, case management and laboratory systems strengthening

Philomena Raftery,Orla Condell,Christine Wasunna,Jonathan Kpaka,Ruth Zwizwai,Mahmood Nuha,Mosoka Fallah,Maxwell Freeman,Victoria Harris,Mark Miller,April Baller,Moses Massaquoi,Victoria Katawera,John Saindon,Philip Bemah,Esther Hamblion,Evelyn Castle,Desmond Williams,Alex Gasasira,Tolbert Nyenswah

DOI: https://doi.org/10.1371/journal.pntd.0006135

2018-01-05

Abstract:The 2014-16 Ebola Virus Disease (EVD) outbreak in West Africa highlighted the necessity for readily available, accurate and rapid diagnostics. The magnitude of the outbreak and the re-emergence of clusters of EVD cases following the declaration of interrupted transmission in Liberia, reinforced the need for sustained diagnostics to support surveillance and emergency preparedness. We describe implementation of the Xpert Ebola Assay, a rapid molecular diagnostic test run on the GeneXpert platform, at a mobile laboratory in Liberia and the subsequent impact on EVD outbreak response, case management and laboratory system strengthening. During the period of operation, site coordination, management and operational capacity was supported through a successful collaboration between Ministry of Health (MoH), World Health Organization (WHO) and international partners. A team of Liberian laboratory technicians were trained to conduct EVD diagnostics and the laboratory had capacity to test 64-100 blood specimens per day. Establishment of the laboratory significantly increased the daily testing capacity for EVD in Liberia, from 180 to 250 specimens at a time when the effectiveness of the surveillance system was threatened by insufficient diagnostic capacity. During the 18 months of operation, the laboratory tested a total of 9,063 blood specimens, including 21 EVD positives from six confirmed cases during two outbreaks. Following clearance of the significant backlog of untested EVD specimens in November 2015, a new cluster of EVD cases was detected at the laboratory. Collaboration between surveillance and laboratory coordination teams during this and a later outbreak in March 2016, facilitated timely and targeted response interventions. Specimens taken from cases during both outbreaks were analysed at the laboratory with results informing clinical management of patients and discharge decisions. The GeneXpert platform is easy to use, has relatively low running costs and can be integrated into other national diagnostic algorithms. The technology has on average a 2-hour sample-to-result time and allows for single specimen testing to overcome potential delays of batching. This model of a mobile laboratory equipped with Xpert Ebola test, staffed by local laboratory technicians, could serve to strengthen outbreak preparedness and response for future outbreaks of EVD in Liberia and the region.
Fast and Parallel Detection of Four Ebola Virus Species on a Microfluidic-Chip-Based Portable Reverse Transcription Loop-Mediated Isothermal Amplification System

Xue Lin,Xiangyu Jin,Bin Xu,Ruliang Wang,Rongxin Fu,Ya Su,Kai Jiang,Han Yang,Ying Lu,Yong Guo,Guoliang Huang

DOI: https://doi.org/10.3390/mi10110777

IF: 3.4

2019-01-01

Micromachines

Abstract:Considering the lack of official vaccines and medicines for Ebola virus infection, reliable diagnostic methods are necessary for the control of the outbreak and the spread of the disease. We developed a microfluidic-chip-based portable system for fast and parallel detection of four Ebola virus species. The system is based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) and consists of four specific LAMP primers, a disc microfluidic chip, and a portable real-time fluorescence detector. It could specifically and parallelly distinguish four species of the Ebola virus after only one sampling, including the Zaire Ebola virus, the Sudan Ebola virus, the Bundibugyo Ebola virus, and the Tai Forest Ebola virus, without cross-contamination. The limit of detection was as small as 10 copies per reaction, while the total consumption of sample and reagent was 0.94 μL per reaction. The final results could be obtained in 50 min after one addition of sample and reagent mixture. This approach provides simplicity, high sensitivity, and multi-target parallel detection at a low cost, which could enable convenient and effective on-site detections of the Ebola virus in the outdoors, remote areas, and modern hospitals.
Breakthrough curves and elution profiles of single solutes in case of adsorption isotherms with two inflection points.

Weibing Zhang,Y. Shan,A. Seidel-Morgenstern

DOI: https://doi.org/10.1016/J.CHROMA.2005.12.094

IF: 4.601

2006-02-24

Journal of Chromatography A

Abstract:
Pharmacological analysis of the interaction between Bay K 8644 and 5‐HT in rabbit aorta

V. Barrett,P. Leff,G. Martin,P. Richardson

DOI: https://doi.org/10.1111/j.1476-5381.1986.tb10190.x

IF: 7.3

1986-03-01

British Journal of Pharmacology

Abstract:1 Bay K 8644 potentiated and augmented 5‐hydroxytryptamine (5‐HT)‐induced contractions in the rabbit, isolated aorta preparation, as manifested in leftward shift and increase in the asymptote of 5‐HT E/[A] (effect vs concentration) curves. 2 The operational model of agonism (Black & Leff, 1983) was used to analyse this interaction and the concomitant effects of irreversible receptor alkylation by phenoxybenzamine. The competitive effects of spiperone in the presence and absence of Bay K 8644 were also examined. 3 From these analyses it is concluded that Bay K 8644 elicits its potentiating effects by increasing the efficacy of 5‐HT at the 5‐HT2 receptor with no alteration in affinity. This is consistent with the known effect of Bay K 8644 of causing an increase in the functional concentration of plasmalemmal calcium channels coupled to the 5‐HT2 receptors in this preparation. 4 The positively co‐operative shape of the 5‐HT E/[A] curves obtained in the aorta and the quantitative nature of their potentiation by Bay K 8644 indicated that the coupling of 5‐HT2 receptor occupancy to intracellular calcium concentration is linear and that the co‐operativity resides in the subsequent relation between intracellular calcium and pharmacological effect. 5 Bay K 8644 may serve as a probe for differentiating between the types of calcium channels that transduce 5‐HT receptor‐mediated effects in different systems. Such information would be useful in the classification of agonist interactions with 5‐HT receptors.
Diagnostic Strategies for Ebola Virus Detection

Shuo Su,Gary Wong,Xiangguo Qiu,Gary P. Kobinger,Yang Bi,Jiyong Zhou

DOI: https://doi.org/10.1016/s1473-3099(16)00049-9

2016-01-01

Abstract:Mobile laboratories for highly dangerous pathogens were deployed in west Africa during the 2014–16 outbreak of Ebola virus disease. These laboratories have substantially reduced the burden on medical professionals by providing on-site diagnostics.1Mansuy JM Mobile laboratories for Ebola and other pathogens.Lancet Infect Dis. 2015; 15: 1135Summary Full Text Full Text PDF Scopus (11) Google Scholar One study estimated that if 60% of patients with Ebola virus disease are diagnosed within 1 day of symptom onset, instead of the current average of 5 days, the virus attack rate drops from 80% to nearly 0%.2Dhillon RS Srikrishna D Garry RF Chowell G Ebola control: rapid diagnostic testing.Lancet Infect Dis. 2015; 15: 147-148Summary Full Text Full Text PDF PubMed Scopus (36) Google Scholar This finding emphasises the substantial effect of a rapid, accurate, clinical diagnosis of Ebola virus disease supported by laboratory tests. Several diagnostic assays were authorised by the US Food and Drug Administration (FDA) for emergency use during the outbreak (appendix). Here, we analyse the use of the three kits that were also approved by WHO (table): RealStar Filovirus Screen RT-PCR Kit 1.0 (Altona Diagnostics GmbH, Hamburg, Germany),3WHOWHO emergency quality assessment mechanism for EVD IVDs. Public report. Product: RealStar® Filovirus Screen RT-PCR Kit 1.0.http://www.who.int/diagnostics_laboratory/procurement/141125_evd_public_report_altona_v1.pdf?ua=1Date: 2014Google Scholar ReEBOV Antigen Rapid Test Kit (Corgenix, Broomfield, CO, USA),4WHOWHO emergency use assessment and listing for Ebola Virus Disease IVDs. Public report. Product: ReEBOVTM Antigen Rapid Test Kit.http://www.who.int/diagnostics_laboratory/procurement/150219_reebov_antigen_rapid_test_public_report.pdf?ua=1Date: 2015Google Scholar and Xpert Ebola Assay (Cepheid AB, Sunnyvale, CA, USA).5WHOWHO emergency use assessment and listing for EVD IVDs. Public report. Product: Xpert® Ebola Assay.http://www.who.int/medicines/ebola-treatment/150508FinalPublicReportExpertEbola_Cepheid.pdf?ua=1Date: 2015Google ScholarTableAssays for detecting filovirus infections approved for emergency use by the US FDA and WHOManufacturerDetection techniqueViruses detectedTarget viral geneTime to resultsLimit of detectionPatient specimen neededRealStar Filovirus Screen RT-PCR Kit 1.0 (Nov 2014)3WHOWHO emergency quality assessment mechanism for EVD IVDs. Public report. Product: RealStar® Filovirus Screen RT-PCR Kit 1.0.http://www.who.int/diagnostics_laboratory/procurement/141125_evd_public_report_altona_v1.pdf?ua=1Date: 2014Google ScholarAltona Diagnostics GmbHRT-qPCREbola virus, Sudan virus, Reston virus, Tai Forest virus, Bundibugyo virus, Marburg virusL4–6 h (negative), less for a positive1 plaque-forming unit (about 3400 copies) of Ebola virus or Sudan virus per mL plasmaPlasma collected in EDTA, cell-free bodily fluids, swab washesReEBOV Antigen Rapid Test (Feb 2015)4WHOWHO emergency use assessment and listing for Ebola Virus Disease IVDs. Public report. Product: ReEBOVTM Antigen Rapid Test Kit.http://www.who.int/diagnostics_laboratory/procurement/150219_reebov_antigen_rapid_test_public_report.pdf?ua=1Date: 2015Google ScholarCorgenixRapid chromatographic immunoassayEbola virusVP4015–25 min2·11 × 108 RNA copies per mL (extrapolated) or 1 × 108 plaque-forming units per mL (FDA calculated)Finger-prick (capillary) whole blood, venous whole blood, or plasma collected in EDTAXpert Ebola Assay (May 2015)5WHOWHO emergency use assessment and listing for EVD IVDs. Public report. Product: Xpert® Ebola Assay.http://www.who.int/medicines/ebola-treatment/150508FinalPublicReportExpertEbola_Cepheid.pdf?ua=1Date: 2015Google ScholarCepheid ABRT-qPCREbola virusNucleoprotein and glycoprotein90 min82·0 RNA copies per reaction (95% CI 39·7–3193·6)Venous whole blood collected in EDTAFDA=Food and Drug Administration. Open table in a new tab FDA=Food and Drug Administration. The RealStar device is a real-time quantitative PCR (RT-qPCR) test for detecting the L gene. The device takes 4–6 h to provide a negative result, roughly 2 h for a positive result, and has a limit of detection of 1 plaque-forming unit per mL, or about 3400 copies per mL. ReEBOV is a rapid chromatographic immunoassay against VP40; it takes 15–25 min to produce a final result and has a limit of detection of 2·11 × 108 copies per mL (by extrapolation), or 1 × 106 plaque-forming units per mL (FDA calculated6US Food and Drug AdministrationReEBOVTM Antigen Rapid Test (Ebolavirus VP40 antigen detection). Instructions for use.http://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM438511.pdfDate: 2015Google Scholar). The Xpert Ebola Assay is an RT-qPCR test for detecting viral nucleoprotein and glycoprotein. The assay takes 90 min to produce results and has a limit of detection of 82·0 RNA copies per reaction. The ReEBOV test was used in two clinics in Sierra Leone during the Ebola outbreak and was found to be 100% specific for Ebola.7Broadhurst MJ Kelly JD Miller A et al.ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.Lancet. 2015; 386: 867-874Summary Full Text Full Text PDF PubMed Scopus (133) Google Scholar Cycle threshold values of the tested patients ranged from 15·9 to 26·3 (mean 22·6).7Broadhurst MJ Kelly JD Miller A et al.ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.Lancet. 2015; 386: 867-874Summary Full Text Full Text PDF PubMed Scopus (133) Google Scholar However, at these values, most patients will be showing clinical signs of moderate to severe Ebola virus disease, and values less than 20 are associated with terminal disease. Rapid diagnostic tests are also important for detecting and confirming infected patients who have not yet progressed to advanced disease (cycle threshold >30), at a time when they are less infectious to others, and with a greater chance of survival with clinical intervention. The high limit of detection suggests that the ReEBOV test is currently not sufficiently sensitive to optimally inform and manage suspect cases or outbreaks. Rather, in view of the quick turnaround time, the test is more applicable for rapid screening of patients with advanced disease, in whom a positive result would raise the alarm and push for confirmation by RT-qPCR and next-generation sequencing. RT-qPCR-based assays have a lower limit of detection; however, the longer turnaround time plus the time needed for viral RNA extraction suggests that the RealStar test and the Xpert Ebola Assay are better suited to confirmation or diagnosis of suspected cases early after onset of Ebola virus disease. Future research efforts should prioritise lowering the limit of detection of assays based on RT-qPCR to improve diagnostics for Ebola and detect and manage potential outbreaks at the earliest opportunity. This report was partly supported by the National Key Program for Infectious Disease of China (2016ZX10004222-011), the National Key Technology R&D Program of China (2015BAD12B00), the National Natural Science Foundation of China (81590760), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Special Foundation of President for Ebola virus research from Chinese Academy of Sciences. GW is the recipient of a Banting Postdoctoral Fellowship from the Canadian Institutes of Health Research and the President's International Fellowship Initiative from the Chinese Academy of Sciences. We declare no competing interests. Download .pdf (.2 MB) Help with pdf files Supplementary appendix Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological studyThe emergence of MCR-1 heralds the breach of the last group of antibiotics, polymyxins, by plasmid-mediated resistance. Although currently confined to China, MCR-1 is likely to emulate other global resistance mechanisms such as NDM-1. Our findings emphasise the urgent need for coordinated global action in the fight against pan-drug-resistant Gram-negative bacteria. Full-Text PDF
Survey and Visual Detection of Zaire ebolavirus in Clinical Samples Targeting the Nucleoprotein Gene in Sierra Leone

Huan Li,Xuesong Wang,Wei Liu,Xiao Wei,Weishi Lin,Erna Li,Puyuan Li,Derong Dong,Lifei Cui,Xuan Hu,Boxing Li,Yanyan Ma,Xiangna Zhao,Chao Liu,Jing Yuan

DOI: https://doi.org/10.3389/fmicb.2015.01332

IF: 5.2

2015-12-01

Frontiers in Microbiology

Abstract:Ebola virus (EBOV) can lead to severe hemorrhagic fever with a high risk of death in humans and other primates. To guide treatment and prevent spread of the viral infection, a rapid and sensitive detection method is required for clinical samples. Here, we described and evaluated a reverse transcription loop-mediated isothermal amplification (RT-LAMP) method to detect Zaire ebolavirus using the nucleoprotein gene (NP) as a target sequence. Two different techniques were used, a calcein/Mn(2+) complex chromogenic method and real-time turbidity monitoring. The RT-LAMP assay detected the NP target sequence with a limit of 4.56 copies/μL within 45 min under 61°C, a similar even or increase in sensitivity than that of real-time reverse transcription-polymerase chain reaction (RT-PCR). Additionally, all pseudoviral particles or non- Zaire EBOV genomes were negative for LAMP detection, indicating that the assay was highly specific for EBOV. To appraise the availability of the RT-LAMP method for use in clinical diagnosis of EBOV, of 417 blood or swab samples collected from patients with clinically suspected infections in Sierra Leone, 307 were identified for RT-LAMP-based surveillance of EBOV. Therefore, the highly specific and sensitive RT-LAMP method allows the rapid detection of EBOV, and is a suitable tool for clinical screening, diagnosis, and primary quarantine purposes.

microbiology
Paper-based RNA detection and multiplexed analysis for Ebola virus diagnostics

Laura Magro,Béatrice Jacquelin,Camille Escadafal,Pierre Garneret,Aurélia Kwasiborski,Jean-Claude Manuguerra,Fabrice Monti,Anavaj Sakuntabhai,Jessica Vanhomwegen,Pierre Lafaye,Patrick Tabeling

DOI: https://doi.org/10.1038/s41598-017-00758-9

IF: 4.6

2017-05-02

Scientific Reports

Abstract:The most performing techniques enabling early diagnosis of infectious diseases rely on nucleic acid detection. Today, because of their high technicality and cost, nucleic acid amplification tests (NAAT) are of benefit only to a small fraction of developing countries population. By reducing costs, simplifying procedures and enabling multiplexing, paper microfluidics has the potential to considerably facilitate their accessibility. However, most of the studies performed in this area have not quit the lab. This letter brings NAAT on paper closer to the field, by using clinical samples and operating in a resource-limited setting. We first performed isothermal reverse transcription and Recombinase Polymerase Amplification (RT-RPA) of synthetic Ribonucleic Acid (RNA) of Ebola virus using paper microfluidics devices. We further applied this method in Guinea to detect the presence of Ebola virus in human sample RNA extracts, with minimal facilities (carry-on detection device and freeze-dried reagents on paper). RT-RPA results were available in few minutes and demonstrate a sensitivity of 90.0% compared to the gold-standard RT-PCR on a set of 43 patient samples. Furthermore, the realization of a nine-spot multilayered device achieving the parallel detection of three distinct RNA sequences opens a route toward the detection of multiple viral strains or pathogens.

multidisciplinary sciences
Detection and Classification of Ebola on Microfluidic Chips

X Lin,XY Jin,YQ Fan,Q Huang,Y Kou,G Zu,SG Huang,XS Liu,GL Huang

DOI: https://doi.org/10.1117/12.2246154

2017-01-01

Abstract:Point-of-care testing (POCT) for an infectious diseases is the prerequisite to control of the disease and limitation of its spread. A microfluidic chip for detection and classification of four strains of Ebola virus was developed and evaluated. This assay was based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) and specific primers for Ebola Zaire virus, Ebola Sudan virus, Ebola Tai Forest virus and Ebola Bundibugyo virus were designed. The sensitivity of the microfluidic chip was under 103 copies per milliliter, as determined by ten repeated tests. This assay is unique in its ability to enable diagnosis of the Ebola infections and simultaneous typing of Ebola virus on a single chip. It offers short reaction time, ease of use and high specificity. These features should enable POCT in remote area during outbreaks of Ebola virus.
Poor effect of family practice physician training at the organizational level in long-term care facilities in Flanders, Belgium.

J. de Lepeleire,W. Leirman

DOI: https://doi.org/10.1016/J.JAMDA.2006.04.008

IF: 7.802

2006-09-01

Journal of the American Medical Directors Association

Abstract:
Rapid and Fully Microfluidic Ebola Virus Detection with CRISPR-Cas13a

Peiwu Qin,Myeongkee Park,Kendra J Alfson,Manasi Tamhankar,Ricardo Carrion,Jean L Patterson,Anthony Griffiths,Qian He,Ahmet Yildiz,Richard Mathies,Ke Du

DOI: https://doi.org/10.1021/acssensors.9b00239

IF: 8.9

2019-01-01

ACS Sensors

Abstract:Highly infectious illness caused by pathogens is endemic especially in developing nations where there is limited laboratory infrastructure and trained personnel. Rapid point-of-care (POC) serological assays with minimal sample manipulation and low cost are desired in clinical practice. In this study, we report an automated POC system for Ebola RNA detection with RNA-guided RNA endonuclease Cas13a, utilizing its collateral RNA degradation after its activation. After automated microfluidic mixing and hybridization, nonspecific cleavage products of Cas13a are immediately measured by a custom integrated fluorometer which is small in size and convenient for in-field diagnosis. Within 5 min, a detection limit of 20 pfu/mL (5.45 × 107 copies/mL) of purified Ebola RNA is achieved. This isothermal and fully solution-based diagnostic method is rapid, amplification-free, simple, and sensitive, thus establishing a key technology toward a useful POC diagnostic platform. © 2019 American Chemical Society.
The Use of Near-Infrared Light-Emitting Fluorescent Nanodiamond Particles to Detect Ebola Virus Glycoprotein: Technology Development and Proof of Principle

Giora Z Feuerstein,Michael A Mansfield,Peter I Lelkes,Salvatore Alesci,Cezary Marcinkiewicz,Nathan Butlin,Mark Sternberg

DOI: https://doi.org/10.2147/IJN.S261952

IF: 7.033

2020-10-08

International Journal of Nanomedicine

Abstract:Giora Z Feuerstein, 1 Michael A Mansfield, 2 Peter I Lelkes, 3 Salvatore Alesci, 1 Cezary Marcinkiewicz, 1, 3 Nathan Butlin, 4 Mark Sternberg 1 1 Debina Diagnostics Inc., Newtown Square, PA, USA; 2 MilliporeSigma, Bedford, MA, USA; 3 Department of Bioengineering, Temple University, Philadelphia, PA, USA; 4 Axxin Pty Ltd, Fairfield, VIC, Australia Correspondence: Giora Z Feuerstein Debina Diagnostics Inc., Newtown Square, PA, USA Tel +1 4842221575 Email cmarcik@temple.edu Background: There is a dire need for rapid diagnostic tests of high sensitivity, efficiency, and point-of-test reporting capability to mitigate lethal viral epidemic outbreaks. Purpose: To develop a new operating system within the lateral flow assay (LFA) format for Ebola virus (EBOV), based on fluorescent nanodiamond particles (FNDP) nitrogen vacancy (NV) emitting near-infrared (NIR) light. Specifically, we aimed to detail technical issues and the feasibility of mobilizing FNDP-NV on nitrocellulose membranes (NCM) and capturing them at test and control lines. Methods: FNDP-NV-200nm, 400nm or 800nm were linked to anti-EBOV glycoprotein (GP) monoclonal antibodies (mAb) and tested for LFA performance by monitoring NIR emissions using an in vivo imaging system or optoelectronic device (OED). Anti-EBOV recombinant glycoprotein (GP) humanized mAb c13C6 was linked to FNDP-NV-200nm for the mobile phase; and a second anti-GP mouse mAb, 6D8, was printed on NCM at the test line. Goat anti-human IgG (GAH-IgG) served as a nonspecific antibody for conjugated FNDP-NV-200nm at the control line. Results: FNDP-NV-200nm-c13C6 specifically and dose-dependently bound to recombinant EBOV GP in vitro and was effectively captured in a sandwich configuration at the test line by mAb 6D8. FNDP-NV-200nm-c13C6 was captured on the control line by GAH-IgG. The OED quantitative analysis of NIR (obtained in less than 1 minute) was further validated by an in vivo imaging system. Conclusion: FNDP-NV-200nm performance as a reporter for EBOV GP rapid diagnostic tests suggests an opportunity to replace contemporary visual tests for EBOV GP and other highly lethal viral pathogens. Mobile, battery-operated OED adds portability, quantitative data, rapid data collection, and point-of-test reporting capability. Further development of FNDP-NV-200nm within a LFA format is justified. Keywords: Ebola virus, diagnostic lateral flow test, LFA, opto-electronic reader, OER, anti-EBOV antibodies, nitrocellulose membranes, fluidics technology

pharmacology & pharmacy,nanoscience & nanotechnology

Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?

Diagnostics of Ebola virus

Development and Evaluation of a Rapid and Sensitive EBOV-RPA Test for Rapid Diagnosis of Ebola Virus Disease

Ebolavirus diagnosis made simple, comparable and faster than molecular detection methods: preparing for the future

Comparative Evaluation of the Diagnostic Performance of the Prototype Cepheid GeneXpert Ebola Assay

Analytical Performance Characteristics of the Cepheid GeneXpert Ebola Assay for the Detection of Ebola Virus

Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus

Digital Rolling Circle Amplification-Based Detection of Ebola and Other Tropical Viruses

Rapid detection of Ebolavirus using isothermal recombinase‐aided amplification

Ebola Virus Disease Diagnostics, Sierra Leone: Analysis of Real-time Reverse Transcription-Polymerase Chain Reaction Values for Clinical Blood and Oral Swab Specimens

Establishing Ebola Virus Disease (EVD) diagnostics using GeneXpert technology at a mobile laboratory in Liberia: Impact on outbreak response, case management and laboratory systems strengthening

Fast and Parallel Detection of Four Ebola Virus Species on a Microfluidic-Chip-Based Portable Reverse Transcription Loop-Mediated Isothermal Amplification System

Breakthrough curves and elution profiles of single solutes in case of adsorption isotherms with two inflection points.

Pharmacological analysis of the interaction between Bay K 8644 and 5‐HT in rabbit aorta

Diagnostic Strategies for Ebola Virus Detection

Survey and Visual Detection of Zaire ebolavirus in Clinical Samples Targeting the Nucleoprotein Gene in Sierra Leone

Paper-based RNA detection and multiplexed analysis for Ebola virus diagnostics

Detection and Classification of Ebola on Microfluidic Chips

Poor effect of family practice physician training at the organizational level in long-term care facilities in Flanders, Belgium.

Rapid and Fully Microfluidic Ebola Virus Detection with CRISPR-Cas13a

The Use of Near-Infrared Light-Emitting Fluorescent Nanodiamond Particles to Detect Ebola Virus Glycoprotein: Technology Development and Proof of Principle